Narcolepsy market accounted for US$ 1.797 billion in 2020 and is estimated to be US$ 4.205 billion by 2030 and is anticipated to register a CAGR of 8.9%. Narcolepsy is a medical condition marked by excessive daytime sleepiness and irregular sleep patterns. As a result of this chronic sleep disorder, an abrupt loss of muscular tone (cataplexy) can occur, resulting in weakness and loss of muscle control. Sleep paralysis, hallucinations, daytime sleepiness, fragmented sleep, and insomnia are some of the most common symptoms of the illness. Cataplexy, a rapid decrease of muscle strength that has been found to have a major influence on patients' emotional well-being, affects about 70% of persons. Inability to move or vivid hallucinations may occur when falling asleep or waking up.
The report " Global Narcolepsy Market, By Type (Type 1 and Type 2 Narcolepsy), By Treatment (Antidepressants, Stimulants, Sodium oxybate and Others), By Diagnosis (Poysomnogram, Multiple sleep latency test and Others), By End Users (Hospitals, Retail Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”
Key Highlights:
Adare Pharmaceuticals and NLS Pharmaceutics teamed together in January 2020 to develop a mazindol CR product candidate for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD).
Analyst View:
The key factors pushing the market for narcolepsy drugs to increase are the severity of the disease and the number of people affected by it. Sleep apnea can be treated using narcolepsy drugs. Demand is further boosted by the availability of a payment method for FDA-approved prescription medications. Additionally, rising disposable income and increased awareness of the benefits of narcolepsy drugs are likely to propel the global market forward. Rising narcolepsy prevalence and a growing obese population are the key factors of narcolepsy market growth over the forecast period.
Before purchasing this report, request a sample or make an inquiry by clicking the following link:
Key Market Insights from the report:
The global Narcolepsy market accounted for US$ 1.797 billion in 2020 and is estimated to be US$ 4.205 billion by 2030 and is anticipated to register a CAGR of 8.9%. The Global Narcolepsy Market is segmented based on the type, treatment, diagnosis, end-user, and region.
By Type, the Global Narcolepsy Market is segmented into Type 1 and Type 2.
By Treatment, the market is segmented in Antidepressants, Stimulants, Sodium oxybate and Others.
By Diagnosis, the Global Narcolepsy Market is segmented into Poysomnogram, Multiple sleep latency test and Others.
By Region, the Global Narcolepsy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. America dominates the global narcolepsy market.
Competitive Landscape:
The key players operating in the global Narcolepsy market includes Jazz Pharmaceuticals plc., BIOPROJET, Arena Pharmaceuticals, Inc., Graymark Healthcare, Inc., Mylan N.V. Teva Pharmaceutical Industries Ltd., Novartis AG, Shire, Shionogi Inc., Ligand Pharmaceuticals, Inc., and Others.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
Narcolepsy market accounted for US$ 1.797 billion in 2020 and is estimated to be US$ 4.205 billion by 2030 and is anticipated to register a CAGR of 8.9%. Narcolepsy is a medical condition marked by excessive daytime sleepiness and irregular sleep patterns. As a result of this chronic sleep disorder, an abrupt loss of muscular tone (cataplexy) can occur, resulting in weakness and loss of muscle control. Sleep paralysis, hallucinations, daytime sleepiness, fragmented sleep, and insomnia are some of the most common symptoms of the illness. Cataplexy, a rapid decrease of muscle strength that has been found to have a major influence on patients' emotional well-being, affects about 70% of persons. Inability to move or vivid hallucinations may occur when falling asleep or waking up.
The report " Global Narcolepsy Market, By Type (Type 1 and Type 2 Narcolepsy), By Treatment (Antidepressants, Stimulants, Sodium oxybate and Others), By Diagnosis (Poysomnogram, Multiple sleep latency test and Others), By End Users (Hospitals, Retail Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”
Key Highlights:
Adare Pharmaceuticals and NLS Pharmaceutics teamed together in January 2020 to develop a mazindol CR product candidate for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD).
Analyst View:
The key factors pushing the market for narcolepsy drugs to increase are the severity of the disease and the number of people affected by it. Sleep apnea can be treated using narcolepsy drugs. Demand is further boosted by the availability of a payment method for FDA-approved prescription medications. Additionally, rising disposable income and increased awareness of the benefits of narcolepsy drugs are likely to propel the global market forward. Rising narcolepsy prevalence and a growing obese population are the key factors of narcolepsy market growth over the forecast period.
Before purchasing this report, request a sample or make an inquiry by clicking the following link:
Key Market Insights from the report:
The global Narcolepsy market accounted for US$ 1.797 billion in 2020 and is estimated to be US$ 4.205 billion by 2030 and is anticipated to register a CAGR of 8.9%. The Global Narcolepsy Market is segmented based on the type, treatment, diagnosis, end-user, and region.
By Type, the Global Narcolepsy Market is segmented into Type 1 and Type 2.
By Treatment, the market is segmented in Antidepressants, Stimulants, Sodium oxybate and Others.
By Diagnosis, the Global Narcolepsy Market is segmented into Poysomnogram, Multiple sleep latency test and Others.
By Region, the Global Narcolepsy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. America dominates the global narcolepsy market.
Competitive Landscape:
The key players operating in the global Narcolepsy market includes Jazz Pharmaceuticals plc., BIOPROJET, Arena Pharmaceuticals, Inc., Graymark Healthcare, Inc., Mylan N.V. Teva Pharmaceutical Industries Ltd., Novartis AG, Shire, Shionogi Inc., Ligand Pharmaceuticals, Inc., and Others.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
